Triple Negative Breast Cancer
Conditions
Keywords
Programmed Death-1
Brief summary
This study is to evaluate the efficacy and safety for dose-dense epirubicin hydrochloride with cyclophosphamide followed by nanoparticlealbumin-bound paclitaxel with PD-1 in neoadjuvant therapy for patients with triple-negative breast cancer, and to explore the predictive value of biological markers for the treatment.
Detailed description
This study is an open single arm study, which would undergo optimal two stage designs. 60 patients who are diagnosed with triple-negative breast cancer would have dose-dense epirubicin hydrochloride with cyclophosphamide followed by nanoparticlealbumin-bound paclitaxel with PD-1 regimen for neoadjuvant therapy if they meet the eligibility criteria. The regimen is as follows: epirubicin hydrochloride (90mg/m2, d1) plus cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles, followed by nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles, and Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles. pathological complete response would be the primary endpoint. The change of biological markers and safety of the regimen would also be evaluated.
Interventions
DRUGepirubicin hydrochloride
Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
DRUGCyclophosphamide
Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
DRUGToripalimab
Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 to 70 years old, female. * Patients with histologically confirmed unilateral primary invasive breast cancer who meet the criteria of cT2-4NanyM0. * Patients with ER negative and PR negative by immunohistochemistry (IHC), and HER-2 negative disease. HER2-negative disease was defined as follows: disease whose HER-2 is 1+ or negative by IHC, or fluorescence in situ hybridization (FISH) is negative if IHC is 2+. * According to the RECIST 1.1 criteria, there is at least one measurable objective lesion. * Eastern Cooperative Oncology Group (ECOG) performance score 0-1. * Baseline left ventricular ejection fraction (LVEF) is greater than or equal to (\>/=) 55%. * Bone marrow function is required as follows: neutrophils are more than or equal to (\>/=) 1.5×109/L, platelets more than or equal to (\>/=) 100×109/L, and hemoglobin more than or equal to (\>/=) 90g/L. * Hepatic and renal function are required as follows: serum creatinine is less than or equal to (\</=) 1.5 times of upper limits of normal (ULN), aspartate transaminase (AST) and alanine aminotransferase (ALT) less than or equal to (\</=) 2.5 times of ULN, and total bilirubin less than or equal to (\</=) 1.5 times of ULN or \</= 2.5 times of ULN if patient is with Gilbert's syndrome. * With good compliance with the planned treatment, are able to understand the follow-up procedures of this study and sigh the informed consent form. Signed informed consent.
Exclusion criteria
* Received radiotherapy, chemotherapy, surgery or other targeted and immunotherapy for triple-negative breast cancer before enrollment. * With heart disease classified as New York Heart Association class (NYHA) grade II or above (including grade II) are identified by the investigator. * With severe systemic infection or those with other serious illnesses. * Known to be allergic or intolerant to chemotherapy drugs or their excipients. * With a history of autoimmune diseases or those using glucocorticoids or immunosuppressive drugs. * With known active stage of HBV or HCV infection or hepatitis B DNA ≥500, or patients with chronic abnormal liver function. * With a history of abnormal thyroid function. * With grade ≥ 2 peripheral neuropathy. * With a clear history of neurological or mental disorders, including epilepsy or dement. * Previous non-breast malignancy within 5 years prior to study entry excluding healed cervical carcinoma in situ and non-melanoma skin cancer. * History of other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ and non-melanoma skin cancer. * Pregnancy or lactation, and patients of childbearing potential who refuse to use adequate contraception during the course of this study. * Prior participation in other studies within 30 days prior to the administration of the first dose of the investigational drug. * Patients who are deemed to be unsuitable for this study by investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Pathologic complete response (tpCR) | Immediately after the surgery | Defined as no residual invasive cancer cells are found in the pathological examination of breast and axillary lymph node; if only residual in situ cancer cells are present in the surgical specimens, it can also be considered as achieving a pathological complete response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | Immediately after the surgery | Defined as the proportion of patients with a complete or partial response by MRI. |
| Breast conservative surgery rate | Immediately after the surgery | Defined as the percentage of patients who undergo breast-conserving surgery after neoadjuvant therapy, out of the total number of evaluable cases. |
| Breast pathologic complete response (bpCR: ypT0/is) rate | Immediately after the surgery | Defined as the absence of invasive cancer cells in breast. |
| Adverse events (AEs) | During this period between the start of randomization and the last visit, approximately 3 years | Refer to any untoward medical occurrence in a study subject administered an investigational product which does not necessarily have a causal relationship with the treatment. AE is assessed according to the NCI-CTCAE 5.0. |
| Change in immune-related tissue biomarkers | At baseline, at the end of first 2 cycles (each cycle is 14 days) and immediately after the surgery | The proportion of Tumor-infiltrating lymphocytes (TILs) is evaluated through HE staining. Immunohistochemical staining of PD-1, PD-L1, AR, CD8, and FOXC1) is performed. TILs, PD1, PD-L1, AR, CD8, and FOXC1 in tumor samples by biopsy at baseline, at the end of Cycle 2 and by surgery immediately after surgery would be evaluated by HE or immune staining. |
| Event-free survival (EFS) | Approximately 3 years | Defined as the time from the date of the first study dose to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause. |
Countries
China
Outcome results
None listed